AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8652243 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Number of subjects: 30
Study 2190476 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux‐Y gastrojejunostomy
Number of subjects: 121
Study 2190476 — intervention group
Group type: COMPARATOR
Intervention: Gastroduodenostomy (Billroth I)
Number of subjects: 121
Study 373393 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium chloride (1500 mg daily)
Number of subjects: 40
Study 373393 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (50 mg daily)
Number of subjects: 40
Study 373393 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiloride (5 mg daily)
Number of subjects: 40
Study 373393 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamterene (75 mg daily)
Number of subjects: 40
Study 373393 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (50 mg daily)
Number of subjects: 40
Study 31042551 — intervention group
Group type: EXPERIMENTAL
Intervention: bucindolol
Number of subjects: 267
Study 31042551 — intervention group
Group type: COMPARATOR
Intervention: metoprolol
Number of subjects: 267
Study 28289112 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief intervention conducted by general practitioners (FRAMES model)
Number of subjects: 261
Study 28289112 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 261
Study 25933559 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesh fixation with metal non-absorbable tackers (Group I)
Number of subjects: 63
Study 25933559 — intervention group
Group type: COMPARATOR
Intervention: No fixation of mesh (Group II)
Number of subjects: 63
Study 23535872 — intervention group
Group type: EXPERIMENTAL
Intervention: PGS singletons
Number of subjects: 113
Study 23535872 — intervention group
Group type: EXPERIMENTAL
Intervention: PGS twins
Number of subjects: 113
Study 23535872 — intervention group
Group type: COMPARATOR
Intervention: Control singletons
Number of subjects: 113
Study 23535872 — intervention group
Group type: COMPARATOR
Intervention: Control twins
Number of subjects: 113
Study 21861935 — intervention group
Group type: EXPERIMENTAL
Intervention: Hylan G-F 20 injections (4 courses of 3 × 2.0 ml at 6 month intervals)
Number of subjects: 78
Study 21861935 — intervention group
Group type: COMPARATOR
Intervention: Usual care for knee OA without injections
Number of subjects: 78
Study 19718004 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodontal therapy combined with tacrolimus
Number of subjects: 16
Study 19718004 — intervention group
Group type: COMPARATOR
Intervention: Oral hygiene instructions only (Control)
Number of subjects: 16
Study 17230289 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 IU Syntocinon (in 30 ml N saline)
Number of subjects: 54
Study 17230289 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mcg misoprostol (in 30 ml N saline)
Number of subjects: 54
Study 17230289 — intervention group
Group type: COMPARATOR
Intervention: 30 ml N saline (control)
Number of subjects: 54
Study 16083168 — intervention group
Group type: EXPERIMENTAL
Intervention: Lomefloxacin 0.3%
Number of subjects: 40
Study 16083168 — intervention group
Group type: COMPARATOR
Intervention: Fortified cefazolin and gentamicin
Number of subjects: 40
Study 11561233 — intervention group
Group type: EXPERIMENTAL
Intervention: Core suture methods (Kessler, modified Kessler, Savage, Lee, augmented Becker, or Tsuge finished with a circumferential running suture)
Number of subjects: 118
Study 11561233 — intervention group
Group type: COMPARATOR
Intervention: Repairs without the core suture (including unrepaired tendons)
Number of subjects: 118
Study 9776437 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2D6*1/CYP2D6*1 (homozygous)
Number of subjects: 36
Study 9776437 — intervention group
Group type: COMPARATOR
Intervention: CYP2D6*1/CYP2D6*4 (heterozygous)
Number of subjects: 36
Study 7821456 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tetracycline (250 mg twice daily for 12 weeks)
Number of subjects: 30
Study 7821456 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tetracycline (250 mg twice daily for 12 weeks) and topical prednisolone (for the first 7 days)
Number of subjects: 30
Study 7821456 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (Control group A)
Number of subjects: 30
Study 2839579 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal sprays of recombinant beta serine interferon (rIFN‐beta ser)
Number of subjects: 120
Study 2839579 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily nasal drops of rIFN‐beta ser
Number of subjects: 120
Study 2839579 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 2839579 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose rIFN‐beta ser
Number of subjects: 120
Study 2839579 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose rIFN‐beta ser
Number of subjects: 120
Study 31258916 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep protocol (n=26)
Number of subjects: 56
Study 31258916 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n=30)
Number of subjects: 56
Study 27779917 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of provided checklists during appointments
Number of subjects: 0
Study 27779917 — intervention group
Group type: COMPARATOR
Intervention: Not asked to use checklists but had them available
Number of subjects: 0
Study 26053242 — intervention group
Group type: EXPERIMENTAL
Intervention: Carpal Tunnel Release (CTR)
Number of subjects: 30
Study 23531037 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepcidin-25
Number of subjects: 49
Study 23531037 — intervention group
Group type: COMPARATOR
Intervention: Urine hepcidin-1 in megalin-deficient mice
Number of subjects: 49
Study 23531037 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepcidin-25 post-cardiac surgery
Number of subjects: 49
Study 21697156 — intervention group
Group type: EXPERIMENTAL
Intervention: Digora (PSP system) and film
Number of subjects: 110
Study 21697156 — intervention group
Group type: EXPERIMENTAL
Intervention: VistaScan (PSP system) and film
Number of subjects: 110
Study 21697156 — intervention group
Group type: COMPARATOR
Intervention: Film
Number of subjects: 110
Study 20128295 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) applied at 2 Hz/100 Hz, 4-6 V to specific acupuncture points 30 min before colonoscopy.
Number of subjects: 60
Study 20128295 — intervention group
Group type: COMPARATOR
Intervention: Control group (no electroacupuncture).
Number of subjects: 60
Study 20128295 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA).
Number of subjects: 60
Study 20128295 — intervention group
Group type: COMPARATOR
Intervention: Electroacupuncture (EA) and Control group.
Number of subjects: 60
Study 18200775 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (twice-daily)
Number of subjects: 0
Study 18200775 — intervention group
Group type: COMPARATOR
Intervention: ACE inhibitors
Number of subjects: 0
Study 14741066 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release lovastatin (20 mg)
Number of subjects: 179
Study 14741066 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release lovastatin (20 mg)
Number of subjects: 179
Study 11716446 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cyclophosphamide 50 mg/day and tamoxifen 20 mg/day plus 1‐hexylcarbamoyl‐5‐fluorouracil 300 mg/day for 2 years
Number of subjects: 785
Study 11716446 — intervention group
Group type: COMPARATOR
Intervention: Oral cyclophosphamide 50 mg/day and tamoxifen 20 mg/day for 2 years
Number of subjects: 785
Study 9159449 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonographic findings in karyotypically normal pregnancies
Number of subjects: 137
Study 9159449 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonographic findings in pregnancies with abnormal karyotypes
Number of subjects: 137
Study 9159449 — intervention group
Group type: COMPARATOR
Intervention: Comparison of ultrasonographic findings between normal and abnormal karyotypes
Number of subjects: 137
Study 8503964 — intervention group
Group type: EXPERIMENTAL
Intervention: Birth center care
Number of subjects: 1230
Study 8503964 — intervention group
Group type: COMPARATOR
Intervention: Standard obstetric care
Number of subjects: 1230
Study 3029258 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline (3 micrograms/min) i.v. for 150 min
Number of subjects: 6
Study 3029258 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic ovine corticotrophin-releasing factor-41 (oCRF-41; 25 micrograms)
Number of subjects: 6
Study 3029258 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic ovine corticotrophin-releasing factor-41 (oCRF-41; 50 micrograms)
Number of subjects: 6
Study 3029258 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 6
Study 29720328 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine mouthwash
Number of subjects: 0
Study 29720328 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorine mouthwash
Number of subjects: 0
Study 29720328 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential oils mouthwash
Number of subjects: 0
Study 29720328 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific mouthwash mentioned)
Number of subjects: 0
Study 26626823 — intervention group
Group type: COMPARATOR
Intervention: Normal energy food foam (NEF1, 280 kJ/400 mL)
Number of subjects: 72
Study 26626823 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low energy food foam (VLEF, 36 kJ/400 mL)
Number of subjects: 72
Study 26626823 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative normal energy foam (NEF2)
Number of subjects: 72
Study 26626823 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative normal energy foam (NEF3)
Number of subjects: 72
Study 26626823 — intervention group
Group type: EXPERIMENTAL
Intervention: All foams
Number of subjects: 72
Study 24814695 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal irrigator (Group A)
Number of subjects: 1134
Study 24814695 — intervention group
Group type: EXPERIMENTAL
Intervention: Homemade nasal irrigation connector combined with enemator (Group B)
Number of subjects: 1134
Study 24814695 — intervention group
Group type: COMPARATOR
Intervention: Nasal sprayer (Group C)
Number of subjects: 1134
Study 23136318 — intervention group
Group type: EXPERIMENTAL
Intervention: GEL (lubricant gel use before speculum insertion)
Number of subjects: 400
Study 23136318 — intervention group
Group type: COMPARATOR
Intervention: NO GEL (no lubricant gel use before speculum insertion)
Number of subjects: 400
Study 23136318 — intervention group
Group type: EXPERIMENTAL
Intervention: GEL (lubricant gel use) in premenopausal women
Number of subjects: 400
Study 23136318 — intervention group
Group type: EXPERIMENTAL
Intervention: GEL (lubricant gel use) in postmenopausal women
Number of subjects: 400
Study 23136318 — intervention group
Group type: EXPERIMENTAL
Intervention: GEL (lubricant gel use) in women of reproductive age
Number of subjects: 400
Study 23136318 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytological interpretations of the Papanicolaou test specimens
Number of subjects: 400
Study 20032194 — intervention group
Group type: EXPERIMENTAL
Intervention: Vabicaserin (oral administration)
Number of subjects: 0
Study 20032194 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro (CO2-enriched environment)
Number of subjects: 0
Study 20032194 — intervention group
Group type: EXPERIMENTAL
Intervention: Vabicaserin metabolism
Number of subjects: 0
Study 18589314 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterine artery embolization (UAE)
Number of subjects: 177
Study 18589314 — intervention group
Group type: COMPARATOR
Intervention: Hysterectomy
Number of subjects: 177
Study 15750171 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-time graphical analysis of 18F-fluoro-L-DOPA uptake constant (K(i), min(−1)) in basal ganglia
Number of subjects: 35
Study 15750171 — intervention group
Group type: EXPERIMENTAL
Intervention: SPM analysis of 18F-fluoro-L-DOPA uptake constant (K(i), min(−1)) in basal ganglia
Number of subjects: 35
Study 15750171 — intervention group
Group type: EXPERIMENTAL
Intervention: All-brain SPM analysis
Number of subjects: 35
Study 12585100 — intervention group
Group type: EXPERIMENTAL
Intervention: Kidney tonifying method
Number of subjects: 44
Study 12585100 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 10731009 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine (Cr) supplementation
Number of subjects: 23
Study 10731009 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 9147856 — intervention group
Group type: EXPERIMENTAL
Intervention: Clodronate 3 x 800 mg orally
Number of subjects: 22
Study 9147856 — intervention group
Group type: COMPARATOR
Intervention: Control group (no clodronate)
Number of subjects: 22
Study 1491771 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclic hormone replacement therapy with conjugated estrogens (0.625 mg and 1.25 mg) and progestagens (medroxyprogesterone acetate or medrogestone)
Number of subjects: 363
Study 3161007 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefaclor
Number of subjects: 2026
Study 3161007 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin
Number of subjects: 2026
Study 30453972 — intervention group
Group type: EXPERIMENTAL
Intervention: CID+ patients (≥100 mL decrease in FEV1, ≥4-unit increase in SGRQ score, or moderate/severe exacerbation)
Number of subjects: 4312
Study 30453972 — intervention group
Group type: EXPERIMENTAL
Intervention: CID+ patients
Number of subjects: 4312
Study 26646197 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Check-Up (FCU) intervention
Number of subjects: 0
Study 25144818 — intervention group
Group type: EXPERIMENTAL
Intervention: WE + ILP
Number of subjects: 69
Study 25144818 — intervention group
Group type: COMPARATOR
Intervention: WE
Number of subjects: 69
Study 22520669 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-monthly GP visits (intensive care)
Number of subjects: 1200
Study 22520669 — intervention group
Group type: COMPARATOR
Intervention: Usual GP care (opportunistic care)
Number of subjects: 1200
Study 20479407 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel added to adjuvant doxorubicin plus cyclophosphamide (AC) chemotherapy
Number of subjects: 1581
Study 20479407 — intervention group
Group type: COMPARATOR
Intervention: AC chemotherapy alone
Number of subjects: 1581
Study 18752330 — intervention group
Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil (ADV) 10 mg
Number of subjects: 171
Study 16042933 — intervention group
Group type: EXPERIMENTAL
Intervention: Single high-fluence purpuric pass
Number of subjects: 9
Study 16042933 — intervention group
Group type: COMPARATOR
Intervention: Four low-fluence subpurpuric passes
Number of subjects: 9
Study 14521275 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard EEG
Number of subjects: 157
Study 14521275 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard EEG with focal epileptiform activity
Number of subjects: 157
Study 14521275 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG with sleep deprivation
Number of subjects: 157
Study 14521275 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine EEG
Number of subjects: 157
Study 14521275 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroradiological examinations
Number of subjects: 157
Study 10926637 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 g/day of pyruvate
Number of subjects: 7
Study 10926637 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 8874117 — intervention group
Group type: COMPARATOR
Intervention: Mask CPAP for 20 min (group A, n = 24)
Number of subjects: 103
Study 8874117 — intervention group
Group type: COMPARATOR
Intervention: Volume expansion with 9 ml of 3 ml albumin, 3 ml glucose, and 3 mEq of sodium bicarbonate (group B, n = 24)
Number of subjects: 103
Study 8874117 — intervention group
Group type: COMPARATOR
Intervention: Volume expansion with 4.5 ml albumin and 4.5 ml glucose (group C, n = 14)
Number of subjects: 103
Study 31581591 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein supplement enriched with leucine
Number of subjects: 28
Study 31581591 — intervention group
Group type: COMPARATOR
Intervention: Placebo supplementation
Number of subjects: 28
Study 29075885 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 165
Study 29075885 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 165
Study 29075885 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 165
Study 29075885 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 165
Study 26721653 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin treatment
Number of subjects: 400
Study 26721653 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin replacement
Number of subjects: 400
Study 24467672 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency vessel-sealing system (LF1212 group)
Number of subjects: 100
Study 24467672 — intervention group
Group type: COMPARATOR
Intervention: Clamp-crushing technique (Kelly group)
Number of subjects: 100
Study 24467672 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study 22385885 — intervention group
Group type: EXPERIMENTAL
Intervention: 10mg fluvastatin/20mg valsartan daily for 30 days
Number of subjects: 40
Study 22385885 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 18344726 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine treatment for 6 weeks
Number of subjects: 112
Study 16826400 — intervention group
Group type: EXPERIMENTAL
Intervention: Psilocybin (30 mg/70 kg)
Number of subjects: 30
Study 16826400 — intervention group
Group type: COMPARATOR
Intervention: Methylphenidate hydrochloride (40 mg/70 kg)
Number of subjects: 30
Study 14655885 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (ESWT) - 3 sessions of 3000 shock waves/session at 0.2 mJ/mm2, weekly intervals
Number of subjects: 47
Study 14655885 — intervention group
Group type: COMPARATOR
Intervention: Conventional conservative treatment (iontophoresis with diclofenac and oral NSAID) for 12 weeks followed by ESWT protocol
Number of subjects: 47
Study 11035668 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 2,000 microg via metered‐dose inhaler for 5 consecutive days
Number of subjects: 12
Study 11035668 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 9120655 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse case manager intervention
Number of subjects: 478
Study 9120655 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 478
Study 1570496 — intervention group
Group type: EXPERIMENTAL
Intervention: diclofenac/misoprostol
Number of subjects: 339
Study 1570496 — intervention group
Group type: COMPARATOR
Intervention: diclofenac/placebo
Number of subjects: 339
Study 2580176 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute angiotensin-converting enzyme (ACE) inhibition
Number of subjects: 0
Study 2580176 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic angiotensin-converting enzyme (ACE) inhibition
Number of subjects: 0
Study 30203681 — intervention group
Group type: EXPERIMENTAL
Intervention: Contraceptive vaginal rings with 300 µg 17β-estradiol and 75-125 µg/day of etonogestrel (ENG)
Number of subjects: 0
Study 30203681 — intervention group
Group type: EXPERIMENTAL
Intervention: Contraceptive vaginal rings with 300 µg 17β-estradiol and 500-900 µg/day of nomegestrol acetate (NOMAC)
Number of subjects: 0
Study 30203681 — intervention group
Group type: EXPERIMENTAL
Intervention: ENG-E2 125/300 µg/day group
Number of subjects: 0
Study 30203681 — intervention group
Group type: COMPARATOR
Intervention: NuvaRing (ENG/ethinylestradiol 120/15 µg)
Number of subjects: 0
Study 27472648 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard cancer care plus systematic EPC (n = 107)
Number of subjects: 207
Study 27472648 — intervention group
Group type: COMPARATOR
Intervention: Standard cancer care plus on-demand EPC (n = 100)
Number of subjects: 207
Study 24874006 — intervention group
Group type: EXPERIMENTAL
Intervention: Web‐based Solution‐Focused Brief Therapy (SFBT) intervention (n=131)
Number of subjects: 263
Study 24874006 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group (n=132)
Number of subjects: 263
Study 23327035 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (Group D) - loading dose of 1 microg/kg IV over ten minutes, followed by continuous infusion at 0.5 microg/kg/hr throughout surgery
Number of subjects: 54
Study 23327035 — intervention group
Group type: COMPARATOR
Intervention: Saline (Group S) - same volume as dexmedetomidine infusion
Number of subjects: 54
Study 23327035 — intervention group
Group type: EXPERIMENTAL
Intervention: Final BIS number and sevoflurane concentrations
Number of subjects: 54
Study 20573787 — intervention group
Group type: EXPERIMENTAL
Intervention: 35 micro g Se as l-selenomethionine
Number of subjects: 98
Study 20573787 — intervention group
Group type: EXPERIMENTAL
Intervention: 21 micro g Se as l-selenomethionine
Number of subjects: 98
Study 20573787 — intervention group
Group type: COMPARATOR
Intervention: 0 micro g Se (placebo)
Number of subjects: 98
Study 18043579 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-intensive epirubicin and cyclophosphamide with filgrastim and progenitor cell support (DI-EC)
Number of subjects: 0
Study 18043579 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose anthracycline-based chemotherapy (SD-CT)
Number of subjects: 0
Study 16897413 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Assertive Community Treatment (IACT)
Number of subjects: 149
Study 16897413 — intervention group
Group type: EXPERIMENTAL
Intervention: Assertive Community Treatment only (ACTO)
Number of subjects: 149
Study 16897413 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 149
Study 16897413 — intervention group
Group type: EXPERIMENTAL
Intervention: IACT
Number of subjects: 149
Study 16897413 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTO
Number of subjects: 149
Study 12827120 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA cream with heat for 20 minutes
Number of subjects: 76
Study 12827120 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA cream for 60 minutes without heat
Number of subjects: 76
Study 12827120 — intervention group
Group type: COMPARATOR
Intervention: Placebo with heat
Number of subjects: 76
Study 12827120 — intervention group
Group type: COMPARATOR
Intervention: Placebo without heat
Number of subjects: 76
Study 10917988 — intervention group
Group type: EXPERIMENTAL
Intervention: IPC(foot)
Number of subjects: 45